Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Lawrence Dougan, M.D.,Ph.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K08DK114563 (DOUGAN, MICHAEL LAWRENCE) Sep 1, 2017 - Aug 31, 2022
    NIH/NIDDK
    Regulation of brown fat metabolism by the immune receptor PD-L1
    Role: Principal Investigator
  2. F32CA210568 (DOUGAN, MICHAEL) Jul 1, 2016 - Jun 30, 2017
    NIH/NCI
    Targeting cytokines to the tumor microenivronment using a high affinity single domain antibody to PD-L1
    Role: Principal Investigator
  3. F30AG030298 (DOUGAN, MICHAEL LAWRENCE) Oct 1, 2007 - Sep 30, 2011
    NIH/NIA
    The Contribution of Chronic Inflammation to Pulmonary Adenocarcinoma
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 Jun 22. PMID: 32567084.
    Citations:    
  2. Badran Y, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, Kem M, Zheng H, Borowsky J, Misdraji J, Mino-Kenudson M, Dougan M. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer. 2020 Jun; 8(1). PMID: 32581063.
    Citations:    
  3. Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, Johnson DB, Sullivan RJ, Dougan M. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer. 2020 May; 8(1). PMID: 32414860.
    Citations:    
  4. Abu-Sbeih H, Faleck DM, Dougan M, Wang Y. Reply to Y. Inagaki et al. J Clin Oncol. 2020 May 20; 38(15):1749-1750. PMID: 32250720.
    Citations:    
  5. Dougan M. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Curr Gastroenterol Rep. 2020 Mar 17; 22(4):15. PMID: 32185493.
    Citations:    
  6. Crowley SJ, Bruck PT, Bhuiyan MA, Mitchell-Gears A, Walsh MJ, Zhangxu K, Ali LR, Jeong HJ, Ingram JR, Knipe DM, Ploegh HL, Dougan M, Dougan SK. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biol. 2020 02; 10(2):190235. PMID: 32019478.
    Citations:    
  7. Xie YJ, Dougan M, Ingram JR, Pishesha N, Fang T, Momin N, Ploegh HL. Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. Cancer Immunol Res. 2020 Apr; 8(4):518-529. PMID: 32019780.
    Citations:    
  8. Dougan M, Pietropaolo M. Time to dissect the autoimmune etiology of cancer antibody immunotherapy. J Clin Invest. 2020 Jan 02; 130(1):51-61. PMID: 31895048.
    Citations:    
  9. Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 Feb 20; 38(6):576-583. PMID: 31800340.
    Citations:    
  10. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21. PMID: 31754069.
    Citations:    
  11. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 Mar; 25(3):e398-e404. PMID: 32162817.
    Citations:    
  12. Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology. 2020 Jan; 76(2):233-243. PMID: 31361907.
    Citations:    
  13. Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, Sullivan RJ, Dougan M. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer. 2019 11 07; 7(1):292. PMID: 31699151.
    Citations:    
  14. Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020 01; 25(1):6-14. PMID: 31694890.
    Citations:    
  15. Dougan SK, Dougan M. SMAC mimetics throw a molecular switch to control TH17 responses. Sci Signal. 2019 08 27; 12(596). PMID: 31455724.
    Citations:    
  16. Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFa blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019 08 22; 7(1):226. PMID: 31439050.
    Citations:    
  17. Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 Mar; 82(3):743-746. PMID: 31349048.
    Citations:    
  18. Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, Dougan M. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999. PMID: 31286682.
    Citations:    
  19. Dougan M, Dougan SK. Programmable bacteria as cancer therapy. Nat Med. 2019 07; 25(7):1030-1031. PMID: 31270505.
    Citations:    
  20. Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol. 2019 06; 40(6):511-523. PMID: 31053497.
    Citations:    
  21. Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity. 2019 04 16; 50(4):796-811. PMID: 30995500.
    Citations:    
  22. Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, Momin N, Pishesha N, Rickelt S, Hynes RO, Ploegh H. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci U S A. 2019 04 16; 116(16):7624-7631. PMID: 30936321.
    Citations:    
  23. Bello E, Cohen JV, Mino-Kenudson M, Dougan M. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer. 2019 02 11; 7(1):41. PMID: 30744698.
    Citations:    
  24. Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJL, Dougan M, Garcia KC, Baker D. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019 01; 565(7738):186-191. PMID: 30626941.
    Citations:    
  25. Reynolds K, Thomas M, Dougan M. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist. 2018 09; 23(9):991-997. PMID: 29853659.
    Citations:    Fields:    
  26. Dougan SK, Dougan M. Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy. 2018 07; 10(9):787-796. PMID: 29807457.
    Citations: 1     Fields:    
  27. Krall JA, Reinhardt F, Mercury OA, Pattabiraman DR, Brooks MW, Dougan M, Lambert AW, Bierie B, Ploegh HL, Dougan SK, Weinberg RA. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med. 2018 04 11; 10(436). PMID: 29643230.
    Citations: 2     Fields:    
  28. Ingram JR, Blomberg OS, Rashidian M, Ali L, Garforth S, Fedorov E, Fedorov AA, Bonanno JB, Le Gall C, Crowley S, Espinosa C, Biary T, Keliher EJ, Weissleder R, Almo SC, Dougan SK, Ploegh HL, Dougan M. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A. 2018 04 10; 115(15):3912-3917. PMID: 29581255.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  29. Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT, Ali L, Pishesha N, Blomberg O, Tyler PM, Servos MM, Rashidian M, Nguyen QD, von Andrian UH, Ploegh HL, Dougan SK. Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. Cancer Immunol Res. 2018 04; 6(4):389-401. PMID: 29459478.
    Citations: 2     Fields:    
  30. Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS, Dranoff G, Dougan M, Dougan SK. IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. Cancer Immunol Res. 2018 01; 6(1):25-35. PMID: 29187357.
    Citations: 1     Fields:    
  31. Dougan M. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol. 2017; 8:1547. PMID: 29230210.
    Citations:    
  32. Ingram JR, Dougan M, Rashidian M, Knoll M, Keliher EJ, Garrett S, Garforth S, Blomberg OS, Espinosa C, Bhan A, Almo SC, Weissleder R, Lodish H, Dougan SK, Ploegh HL. PD-L1 is an activation-independent marker of brown adipocytes. Nat Commun. 2017 09 21; 8(1):647. PMID: 28935898.
    Citations: 7     Fields:    Translation:AnimalsCells
  33. Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, Dougan M. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10184-10189. PMID: 28874561.
    Citations: 3     Fields:    Translation:Animals
  34. Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, Cragnolini JJ, Bierie B, Gostissa M, Gorman J, Grotenbreg GM, Bhan A, Weinberg RA, Ploegh HL. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017 Aug 07; 214(8):2243-2255. PMID: 28666979.
    Citations: 10     Fields:    Translation:AnimalsCells
  35. Dougan M, Dougan SK. Targeting Immunotherapy to the Tumor Microenvironment. J Cell Biochem. 2017 10; 118(10):3049-3054. PMID: 28332219.
    Citations: 4     Fields:    Translation:HumansAnimals
  36. Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T, Sacham S, Landesman Y, Dougan M, Dougan SK. Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. Mol Cancer Ther. 2017 03; 16(3):428-439. PMID: 28148714.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  37. Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016 May 10; 113(19):E2646-54. PMID: 27091975.
    Citations: 24     Fields:    Translation:AnimalsPHPublic Health
  38. Tafesse FG, Rashidfarrokhi A, Schmidt FI, Freinkman E, Dougan S, Dougan M, Esteban A, Maruyama T, Strijbis K, Ploegh HL. Disruption of Sphingolipid Biosynthesis Blocks Phagocytosis of Candida albicans. PLoS Pathog. 2015 Oct; 11(10):e1005188. PMID: 26431038.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  39. Rashidian M, Keliher E, Dougan M, Juras PK, Cavallari M, Wojtkiewicz GR, Jacobsen J, Edens JG, Tas JM, Victora G, Weissleder R, Ploegh H. The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. ACS Cent Sci. 2015 Jun 24; 1(3):142-147. PMID: 26955657.
    Citations: 14     
  40. Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho HI, Jaenisch R, Celis E, Ploegh HL. Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Cancer Immunol Res. 2013 Aug; 1(2):99-111. PMID: 24459675.
    Citations: 10     Fields:    Translation:AnimalsCells
  41. Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, Dranoff G. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest. 2011 Jun; 121(6):2436-46. PMID: 21537082.
    Citations: 31     Fields:    Translation:AnimalsCells
  42. Yarchoan M, Dougan ML, Tjota MY, Milliner BH, Adler BL, Armah KA, Gooley TA, Close KL, Close J, Hirsch IB. Who will manage American patients with diabetes? Residents' career preferences and perceptions of diabetes care. Endocr Pract. 2011 Mar-Apr; 17(2):235-9. PMID: 21041164.
    Citations: 1     Fields:    Translation:Humans
  43. Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zawel L, Dranoff G. IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med. 2010 Sep 27; 207(10):2195-206. PMID: 20837698.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  44. Dougan M, Dranoff G. The immune response to tumors. Curr Protoc Immunol. 2009 Apr; Chapter 20:Unit 20.11. PMID: 19347848.
    Citations: 9     Fields:    Translation:HumansAnimals
  45. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009; 27:83-117. PMID: 19007331.
    Citations: 183     Fields:    Translation:HumansAnimalsCells
  46. Dougan M, Dranoff G. Inciting inflammation: the RAGE about tumor promotion. J Exp Med. 2008 Feb 18; 205(2):267-70. PMID: 18268042.
    Citations: 17     Fields:    Translation:HumansAnimals
  47. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. 2007 Jul; 117(7):1902-13. PMID: 17557120.
    Citations: 72     Fields:    Translation:AnimalsCells
  48. Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood. 2007 Aug 01; 110(3):954-61. PMID: 17483299.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  49. Dougan ML, Chin JL, Solt K, Hansen DE. Rapid cleavage of cyclic tertiary amides of Kemp's triacid: effects of ring structure. Bioorg Med Chem Lett. 2004 Aug 16; 14(16):4153-6. PMID: 15261260.
    Citations: 1     Fields:    Translation:Cells
  50. Zaitseva M, King LR, Manischewitz J, Dougan M, Stevan L, Golding H, Golding B. Human peripheral blood T cells, monocytes, and macrophages secrete macrophage inflammatory proteins 1alpha and 1beta following stimulation with heat-inactivated Brucella abortus. Infect Immun. 2001 Jun; 69(6):3817-26. PMID: 11349047.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Dougan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (183)
Explore
_
Co-Authors (43)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.